Source-grounded facts extracted from Zymeworks Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zymeworks Inc. reported financial results for the first quarter March 31, 2026 (three months ended March 31, 2026).
“On May 7, 2026, Zymeworks Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.”
Zymeworks Inc. entered into Loan Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
“Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).”
Zymeworks Inc. entered into Sale Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
“On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.”
Zymeworks Inc. incurred term loan of $250.0 million with Royalty Pharma Development Funding, LLC at fixed rate maturing December 31, 2042.
“Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).”
Oleg Nodelman was appointed as Director at Zymeworks Inc..
“appointed Mr. Oleg Nodelman, Founder and Portfolio Manager of EcoR1 (as defined below), as a director of the Company, effective as of February 17, 2025.”
Hollings C. Renton resigned as Director at Zymeworks Inc..
“Mr. Hollings C. Renton submitted his resignation from the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), including as chair and member of the Board’s compensation committee, effective December 10, 2024”
Kenneth Galbraith resigned as interim Chief Financial Officer at Zymeworks Inc..
“On August 30, 2024, Mr. Kenneth Galbraith resigned from the positions of interim Chief Financial Officer and as principal financial officer and principal accounting officer of the Company, effective as of the Start Date.”
Leone Patterson was appointed as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks Inc..
“the Company’s board of directors (the “Board”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which was anticipated to be September 1, 2024.”
Leone Patterson was appointed as Executive Vice President, Chief Business Officer and Chief Financial Officer at Zymeworks Inc..
“On July 19, 2024, the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) appointed Ms. Leone Patterson, age 61, as Executive Vice President, Chief Business Officer and Chief Financial Officer of the Company, effective upon her commencement of employment with the Company, which is anticipated to be September 1, 2024”
Zymeworks Inc. reported three months ended March 31, 2024 results: revenue $10.0 million.
“Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.”
Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
“As previously reported, effective March 31, 2024 (the “Separation Date”), Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer.”
Kenneth Galbraith was appointed as interim Chief Financial Officer at Zymeworks Inc..
“the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.”
Dr. Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..
“On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.”
Dr. Neil Gallagher was appointed as director at Zymeworks Inc..
“On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.”
Zymeworks Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 31, 2023.”
Scott Platshon was appointed as director at Zymeworks Inc..
“appointed Mr. Scott Platshon, Partner of EcoR1 (as defined below), as a director of the Company, effective as of February 22, 2024.”
Kenneth Hillan resigned as Director at Zymeworks Inc..
“Dr. Kenneth Hillan submitted his resignation from the Board, including as chair and member of the nominating and corporate governance committee and as member of the research and development committee of the Board, effective February 8, 2024.”
Alessandra Cesano was appointed as Director at Zymeworks Inc..
“appointed Dr. Alessandra Cesano as a director of the Company, effective as of February 8, 2024.”
Zymeworks Inc. entered into Securities Purchase Agreement with certain institutional accredited investors affiliated with EcoR1 Capital, LLC valued at approximately $50 million (effective 2023-12-23).
“On December 23, 2023, Zymeworks Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional accredited investors affiliated with EcoR1 Capital, LLC (collectively, the “Purchasers”).”
Zymeworks Inc. shareholders approved Ratification of appointment of KPMG LLP as auditors for the year ending December 31, 2023 at the 2023-12-07 meeting.
“Proposal 3 – Ratification of Appointment of Auditor 3. The securityholders ratified the appointment of KPMG LLP, chartered professional accountants, as the Company’s auditors for the year ending December 31, 2023. There were 0 broker non-votes for this proposal. Votes For % Votes For Votes Against % Votes Against Votes Abstaining % Votes Abstaining 51,687,701 96.74% 1,319,072 2.47% 424,459 0.79%”
Zymeworks Inc. shareholders approved Advisory vote on the compensation of named executive officers at the 2023-12-07 meeting.
“Proposal 2 – Advisory Vote on the Compensation of Named Executive Officers 2. The securityholders approved, on an advisory and non-binding basis, the compensation of the Company’s named executive officers. There were 4,149,809 broker non-votes for this proposal. Votes For % Votes For Votes Against % Votes Against Votes Abstaining % Votes Abstaining 36,821,646 74.71% 12,028,369 24.41% 431,408 0.88%”
Zymeworks Inc. shareholders approved Election of directors at the 2023-12-07 meeting.
“Proposal 1 – Election of Directors 1. The following nominees were elected as directors to serve until their term expires or until their successors are duly elected or appointed. Nominee Votes For % Votes For Votes Withheld % Votes Withheld Broker Non- Votes Nancy Davidson 48,316,787 98.04% 964,636 1.96% 4,149,809 Derek Miller 46,824,107 95.01% 2,457,316 4.99% 4,149,809 Hollings C. Renton 38,415,977 77.95% 10,865,446 22.05% 4,149,809”
Zymeworks Inc. reported financial results for third quarter 2023.
“On November 7, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.”
Zymeworks Inc. terminated Research and License Agreement with LEO Pharma A/S valued at Upfront payment of $5.0 million received; potential milestone payments up to $74.0 million preclinic (effective 2024-01-25).
“On October 27, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), received written notice from LEO Pharma A/S (“LEO”), stating that LEO has elected to terminate, in its entirety, the Research and License Agreement, by and between Zymeworks BC and LEO, dated October 23, 2018 (the “Research and License Agreement”).”
Lota Zoth departed as Director at Zymeworks Inc..
“Ms. Lota Zoth, a member of the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) notified the Company of her decision not to stand for re-election to the Board at the Company’s next annual meeting of stockholders to be held on or about December 7, 2023.”
Zymeworks Inc. terminated Zanidatamab Zovodotin License and Collaboration Agreement with BeiGene, Ltd. valued at up to $195 million in development and commercial milestone payments and royalties ranging from the h (effective 2023-09-18).
“On September 18, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), and BeiGene, Ltd. (“BeiGene”) entered into a Termination Agreement (the “Termination Agreement”) relating to the License and Collaboration Agreement between Zymeworks BC and BeiGene, relating to the research, development and commercialization of zanidatamab zovodotin (formerly known as ZW49), dated November 26, 2018, as amended on May 25, 2020 and June 2, 2021 (collectively, the “Zanidatamab Zovodotin License and Collaboration Agreement”).”
Zymeworks Inc. reported financial results for three and six months ended June 30, 2023.
“On August 10, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.”
Carlos Campoy was appointed as Director at Zymeworks Inc..
“appointed Mr. Carlos Campoy as a director of the Company, effective as of June 30, 2023.”
Zymeworks Inc.: The Company filed a Certificate of Elimination to eliminate its Series B Participating Preferred Stock, effective upon filing on June 12, 2023, following the termination of the Rights Agreement (effective 2023-06-12).
“the Company filed a Certificate of Elimination with the Secretary of State of the State of Delaware on June 12, 2023, which, effective upon filing, eliminated the Company’s Series B Participating Preferred Stock, par value $0.00001 per share (the “Series B Preferred Stock”).”
Kenneth Galbraith was appointed as President at Zymeworks Inc..
“the board of directors of the Company (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chief Executive Officer and Chair of the Board, as President of the Company to succeed Mr. Klompas in the role of President of the Company, effective as of the Separation Effective Date.”
Neil Klompas departed as President and Chief Operating Officer at Zymeworks Inc..
“On May 17, 2023, Zymeworks Inc. (the “Company”) and Mr. Neil Klompas, the Company’s President and Chief Operating Officer, mutually agreed to terms pursuant to which Mr. Klompas will step down as the Company’s President and Chief Operating Officer and separate from employment effective as of June 30, 2023”
Zymeworks Inc. amended Amended and Restated License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited valued at Amendment to transfer responsibility for the Program to Jazz, with unchanged financial terms except (effective 2023-05-15).
“Amended Jazz Collaboration Agreement As previously disclosed, on October 18, 2022, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), entered into a License and Collaboration Agreement (the “Original Jazz Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”), an affiliate of Jazz Pharmaceuticals, Inc. (“Jazz Inc.”), granting Jazz exclusive rights to develop and commercialize Zymeworks BC’s proprietary bispecific HER2 antibody product candidate known as zanidatamab throughout the world, but excluding existing Asia Pacific territories (other than Japan) already governed by Zymeworks BC’s agreement with BeiGene, Ltd. (the “Territory”). As previously disclosed, as part of the Transactions contemplated by the Transfer Agreement (as these terms are defined below), on May 15, 2023, Zymeworks BC and Jazz entered into an Amended and Restated License and Collaboration Agr”
Zymeworks Inc. reported first quarter ended March 31, 2023 results: net income $24.4 million. Guidance reaffirmed.
“Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics , today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.”
Zymeworks Inc. entered into Stock and Asset Purchase Agreement with Jazz Pharmaceuticals, Inc. (effective 2023-04-25).
“On April 25, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), Zymeworks Biopharmaceuticals Inc. (“ZBI”), a subsidiary of Zymeworks BC, Zymeworks Zanidatamab Inc. (“ZZI”), a subsidiary of ZBI formed in December 2022 focused on the Company’s development program for the Company’s bispecific HER2 antibody product candidate known as zanidatamab, and Jazz Pharmaceuticals, Inc. (“Jazz”), entered into a Stock and Asset Purchase Agreement (the “Transfer Agreement”).”
Derek Miller was appointed as Director at Zymeworks Inc..
“voted to appoint Derek Miller as a director of the Company, effective immediately.”
Zymeworks Inc. terminated Termination and License Agreement with Daiichi Sankyo Co., Ltd. (effective 2023-03-17).
“On March 17, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), and Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”), entered into a Termination and License Agreement (the “Termination and License Agreement”) relating to the Collaboration and Cross License Agreement between Zymeworks BC and Daiichi Sankyo, dated September 26, 2016, as amended on September 25, 2018, July 2, 2021, and June 6, 2022 (collectively, the “Collaboration Agreement”).”
Zymeworks Inc.: Amended and restated bylaws to revise advance notice procedures, meeting adjournment, and board size provisions (effective 2023-03-09).
“On March 9, 2023, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.”
Zymeworks Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $412.5 million, net income $124.3 million ($1.90 per fully diluted share), EPS $1.90 per fully diluted share.
“Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results • 2022 was a year of transformation and change: ◦ reported $412.5 million in total revenue for the year ended December 31, 2022; ◦ reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;”
Zymeworks Inc. updated its the quarter and year ended December 31, 2022 guidance (initiated).
“On January 4, 2023, Zymeworks Inc. (the “Company”) announced certain information relating to the Company’s financial condition as of December 31, 2022, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable debt securities, of approximately $490 million, which excludes the expected zanidatamab-related reimbursements for R&D expenses in the fourth quarter of approximately $30 million. The Company also announced that it expects such cash resources to fund the Company’s current planned operations through at least the end of 2026 (such information, the “Financial Condition Information”).”
Dr. Neil Josephson was removed as Chief Medical Officer at Zymeworks Inc..
“On January 3, 2023, the Company removed Dr. Neil Josephson from the position of Chief Medical Officer, effective immediately.”
Zymeworks Inc. shareholders approved Ratification of Appointment of Auditor at the 2022-12-16 meeting.
“Proposal 3 - Ratification of Appointment of Auditor 3. The securityholders ratified the appointment of KPMG LLP, chartered professional accountants, as the Company’s auditors for the year ending December 31, 2022. There were 0 broker non-votes for this proposal. Votes For %Votes For Votes Against % Votes Against Votes Abstaining %Votes Abstaining 35,682,260 99.36% 177,422 0.49% 54,832 0.15%”
Zymeworks Inc. shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2022-12-16 meeting.
“Proposal 2 - Advisory Vote on the Compensation of Named Executive Officers 2. The securityholders approved on an advisory and non-binding basis the compensation of the Company’s named executive officers. There were 5,897,438 broker non-votes for this proposal. Votes For %Votes For Votes Against % Votes Against Votes Abstaining %Votes Abstaining 25,486,721 84.91% 4,485,962 14.94% 44,393 0.15%”
Zymeworks Inc. shareholders approved Election of Directors at the 2022-12-16 meeting.
“Proposal 1 - Election of Directors 1. The following nominees were elected as directors to serve until their term expires or until their successors are duly elected or appointed. Nominee Votes For % Votes For Votes Withheld % Votes Withheld Broker Non- Votes Troy M. Cox 19,442,093 64.77 % 10,574,983 35.23 % 5,897,438 Kenneth Hillan 21,670,332 72.19 % 8,346,744 27.81 % 5,897,438 Natalie Sacks 21,752,839 72.47 % 8,264,237 27.53 % 5,897,438”
Zymeworks Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. (effective 2022-11-09).
“On November 9, 2022, Zymeworks Inc. (the “Company”) entered into a Sales Agreement, dated as of November 9, 2022, (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”).”
Zymeworks Inc. reported financial results for the third quarter ended September 30, 2022.
“today reported financial results for the third quarter ended September 30, 2022.”
Zymeworks Inc. terminated Open Market Sale Agreement with Jefferies LLC (effective 2022-11-09).
“On October 26, 2022, Zymeworks Inc. (the “Company”) notified Jefferies LLC (“Jefferies”) of its decision to terminate the Open Market Sale Agreement SM , dated as of October 21, 2022, (the “Sales Agreement”) between the Company and Jefferies, effective as of November 9, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.